New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT05981703

Recruiting now Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times

Summary

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe and recommended dose. About 217 participants will take part in this non-randomized, open-label study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Auckland City Hospital
RECRUITING

Auckland, 1023, New Zealand
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010-3012, United States
Hangzhou First Peoples Hospital
RECRUITING

Hangzhou, Zhejiang, 310006, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150000, China
Harbour Cancer and Wellness
RECRUITING

Auckland, 1023, New Zealand
Health New Zealand Te Whatu Ora Lakes Rotorua Hospital
RECRUITING

Rotorua, 3010, New Zealand
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, 430079, China
Icahn School of Medicine At Mount Sinai
RECRUITING

New York, New York, 10029-6504, United States
Icon Cancer Centre Kurralta Park
RECRUITING

Kurralta Park, South Australia, SA 5037, Australia
Jining No1 Peoples Hospital West Branch
RECRUITING

Jining, Shandong, 272000, China
John Theurer Cancer Center Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601-2191, United States
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, WA 6009, Australia
Macquarie University
RECRUITING

North Ryde, New South Wales, NSW 2109, Australia
Providence Portland Medical Center
RECRUITING

Portland, Oregon, 97213-2933, United States
Shanghai East Hospital Branch Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200123, China
Shanghai Pulmonary Hospital
COMPLETED

Shanghai, Shanghai Municipality, 200433, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
RECRUITING

Chengdu, Sichuan, 610071, China
Southside Cancer Care
COMPLETED

Miranda, New South Wales, NSW 2228, Australia
Sylvester Cancer Center, University of Miami
RECRUITING

Miami, Florida, 33136, United States
Taizhou Hospital of Zhejiang Province (East)
COMPLETED

Taizhou, Zhejiang, 317004, China
The First Affiliated Hospital of Anhui Medical Universitygaoxin Branch
RECRUITING

Hefei, Anhui, 230022, China
The First Hospital of China Medical University Hunnan Branch
RECRUITING

Shenyang, Liaoning, 110167, China
The University of Texas Md Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4009, United States
Tongji Hospital,Tongji Medical College of Hustsino French New City Branch
RECRUITING

Wuhan, Hubei, 430101, China
University of Southern California Norris Comprehensive
RECRUITING

Los Angeles, California, 90033, United States
Yale University, Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520-8028, United States
Yantai Yuhuangding Hospital
RECRUITING

Yantai, Shandong, 264000, China

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR SOLID TUMOR